vs
Side-by-side financial comparison of CENTRAL PACIFIC FINANCIAL CORP (CPF) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.
PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $72.9M, roughly 1.0× CENTRAL PACIFIC FINANCIAL CORP). On growth, PUMA BIOTECHNOLOGY, INC. posted the faster year-over-year revenue change (27.7% vs 6.0%). Over the past eight quarters, PUMA BIOTECHNOLOGY, INC.'s revenue compounded faster (31.3% CAGR vs 6.7%).
Central Pacific Bank (CPB) is an American regional commercial bank located throughout the state of Hawaii.
Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.
CPF vs PBYI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $72.9M | $75.5M |
| Net Profit | $20.7M | — |
| Gross Margin | — | 69.3% |
| Operating Margin | — | 22.7% |
| Net Margin | 28.4% | — |
| Revenue YoY | 6.0% | 27.7% |
| Net Profit YoY | 16.7% | — |
| EPS (diluted) | $0.78 | $0.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $72.9M | — | ||
| Q4 25 | $76.3M | $75.5M | ||
| Q3 25 | $74.8M | $54.5M | ||
| Q2 25 | $72.8M | $52.4M | ||
| Q1 25 | $68.8M | $46.0M | ||
| Q4 24 | $58.4M | $59.1M | ||
| Q3 24 | $66.6M | $80.5M | ||
| Q2 24 | $64.0M | $47.1M |
| Q1 26 | $20.7M | — | ||
| Q4 25 | $22.9M | — | ||
| Q3 25 | $18.6M | $8.8M | ||
| Q2 25 | $18.3M | $5.9M | ||
| Q1 25 | $17.8M | $3.0M | ||
| Q4 24 | $11.3M | — | ||
| Q3 24 | $13.3M | $20.3M | ||
| Q2 24 | $15.8M | $-4.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 69.3% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 77.4% |
| Q1 26 | — | — | ||
| Q4 25 | 37.0% | 22.7% | ||
| Q3 25 | 31.6% | 17.6% | ||
| Q2 25 | 32.8% | 12.7% | ||
| Q1 25 | 32.8% | 8.7% | ||
| Q4 24 | 23.0% | 22.6% | ||
| Q3 24 | 25.6% | 27.4% | ||
| Q2 24 | 32.2% | -4.6% |
| Q1 26 | 28.4% | — | ||
| Q4 25 | 30.0% | — | ||
| Q3 25 | 24.8% | 16.2% | ||
| Q2 25 | 25.1% | 11.2% | ||
| Q1 25 | 25.8% | 6.5% | ||
| Q4 24 | 19.4% | — | ||
| Q3 24 | 20.0% | 25.2% | ||
| Q2 24 | 24.7% | -9.6% |
| Q1 26 | $0.78 | — | ||
| Q4 25 | $0.85 | $0.26 | ||
| Q3 25 | $0.69 | $0.17 | ||
| Q2 25 | $0.67 | $0.12 | ||
| Q1 25 | $0.65 | $0.06 | ||
| Q4 24 | $0.42 | $0.40 | ||
| Q3 24 | $0.49 | $0.41 | ||
| Q2 24 | $0.58 | $-0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $97.5M |
| Total DebtLower is stronger | $76.5M | $22.7M |
| Stockholders' EquityBook value | $593.9M | $130.3M |
| Total Assets | $7.5B | $216.3M |
| Debt / EquityLower = less leverage | 0.13× | 0.17× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $97.5M | ||
| Q3 25 | — | $94.4M | ||
| Q2 25 | — | $96.0M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | — | $101.0M | ||
| Q3 24 | — | $96.7M | ||
| Q2 24 | — | $96.8M |
| Q1 26 | $76.5M | — | ||
| Q4 25 | $76.5M | $22.7M | ||
| Q3 25 | $131.5M | $34.0M | ||
| Q2 25 | $131.5M | $45.3M | ||
| Q1 25 | $131.4M | $56.7M | ||
| Q4 24 | $156.3M | $68.0M | ||
| Q3 24 | $156.3M | $79.3M | ||
| Q2 24 | $156.2M | $90.7M |
| Q1 26 | $593.9M | — | ||
| Q4 25 | $592.6M | $130.3M | ||
| Q3 25 | $588.1M | $115.3M | ||
| Q2 25 | $568.9M | $104.7M | ||
| Q1 25 | $557.4M | $97.1M | ||
| Q4 24 | $538.4M | $92.1M | ||
| Q3 24 | $543.7M | $71.1M | ||
| Q2 24 | $518.6M | $48.5M |
| Q1 26 | $7.5B | — | ||
| Q4 25 | $7.4B | $216.3M | ||
| Q3 25 | $7.4B | $202.9M | ||
| Q2 25 | $7.4B | $194.9M | ||
| Q1 25 | $7.4B | $196.2M | ||
| Q4 24 | $7.5B | $213.3M | ||
| Q3 24 | $7.4B | $220.7M | ||
| Q2 24 | $7.4B | $205.0M |
| Q1 26 | 0.13× | — | ||
| Q4 25 | 0.13× | 0.17× | ||
| Q3 25 | 0.22× | 0.30× | ||
| Q2 25 | 0.23× | 0.43× | ||
| Q1 25 | 0.24× | 0.58× | ||
| Q4 24 | 0.29× | 0.74× | ||
| Q3 24 | 0.29× | 1.12× | ||
| Q2 24 | 0.30× | 1.87× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $14.4M |
| Free Cash FlowOCF − Capex | — | $14.4M |
| FCF MarginFCF / Revenue | — | 19.1% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $41.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $97.5M | $14.4M | ||
| Q3 25 | $22.2M | $9.7M | ||
| Q2 25 | $34.3M | $14.1M | ||
| Q1 25 | $20.4M | $3.6M | ||
| Q4 24 | $90.5M | $15.6M | ||
| Q3 24 | $21.3M | $11.0M | ||
| Q2 24 | $25.9M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | $92.3M | $14.4M | ||
| Q3 25 | $21.4M | $9.7M | ||
| Q2 25 | $32.3M | $14.1M | ||
| Q1 25 | $19.6M | $3.6M | ||
| Q4 24 | $75.4M | $15.6M | ||
| Q3 24 | $15.6M | $11.0M | ||
| Q2 24 | $21.3M | $1.0M |
| Q1 26 | — | — | ||
| Q4 25 | 121.0% | 19.1% | ||
| Q3 25 | 28.6% | 17.7% | ||
| Q2 25 | 44.3% | 26.8% | ||
| Q1 25 | 28.4% | 7.7% | ||
| Q4 24 | 129.2% | 26.4% | ||
| Q3 24 | 23.5% | 13.7% | ||
| Q2 24 | 33.2% | 2.1% |
| Q1 26 | — | — | ||
| Q4 25 | 6.8% | 0.0% | ||
| Q3 25 | 1.2% | 0.0% | ||
| Q2 25 | 2.7% | 0.0% | ||
| Q1 25 | 1.3% | 0.1% | ||
| Q4 24 | 25.8% | 0.0% | ||
| Q3 24 | 8.5% | 0.0% | ||
| Q2 24 | 7.3% | 0.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.26× | — | ||
| Q3 25 | 1.20× | 1.10× | ||
| Q2 25 | 1.88× | 2.41× | ||
| Q1 25 | 1.15× | 1.21× | ||
| Q4 24 | 7.98× | — | ||
| Q3 24 | 1.60× | 0.54× | ||
| Q2 24 | 1.64× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
